REGN REGENERON PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 872589 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY18.6%
TTM net income YoY5.2%
TTM EPS YoY8.4%
Revenue 3-yr CAGR8.9%
Net income 3-yr CAGR6.5%
Margins
Gross margin—
Operating margin28.8%
Net margin28.5%
FCF margin22.6%
EBITDA margin31.8%
Returns
ROE14.9%
ROA11.4%
ROIC (approx.)13.2%
Asset turnover0.40x
Leverage & solvency
Liabilities / assets24.6%
Debt / equity0.06x
Current ratio3.35x
Interest coverage104.16x
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio-0.1%
Payout ratio8.0%
Capex / revenue6.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $5.12B | $4.29B | $3.61B | $3.88B | $3.75B | $3.68B | $3.03B | $3.79B |
| R&D expense | $1.79B | $1.63B | $1.54B | $1.63B | $1.48B | $1.42B | $1.33B | $1.41B |
| SG&A expense | $677.80M | $662.10M | $647.70M | $775.00M | $657.80M | $634.20M | $633.00M | $792.20M |
| Operating income | $2.05B | $1.29B | $642.90M | $879.90M | $1.03B | $1.08B | $591.70M | $990.20M |
| Interest expense | $10.60M | $11.00M | $12.90M | $12.20M | $19.30M | $3.60M | $8.70M | $10.50M |
| Pretax income | $2.28B | $1.53B | $831.20M | $1.04B | $1.76B | $1.52B | $905.00M | $958.10M |
| Income tax | $335.40M | $230.90M | $104.00M | $199.10M | $303.30M | $127.10M | $96.30M | $40.40M |
| Net income | $1.95B | $1.30B | $727.20M | $844.60M | $1.46B | $1.39B | $808.70M | $917.70M |
| EBITDA | $2.17B | $1.42B | $766.10M | $1.02B | $1.16B | $1.21B | $718.60M | $1.12B |
| EPS (basic) | 19.16 | 12.62 | 6.99 | — | 14.09 | 13.24 | 7.58 | — |
| EPS (diluted) | 18.45 | 12.23 | 6.75 | — | 13.62 | 12.81 | 7.27 | — |
| Dividends declared per share | 0.94 | 0.94 | 0.94 | 0.88 | 0.88 | 0.88 | 0.88 | — |
| Weighted avg. shares (diluted) | 105.60M | 106.00M | 107.70M | — | 107.20M | 108.60M | 111.20M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $3.66B | $2.46B | $2.96B | $3.12B | $2.51B | $2.00B | $3.09B | $2.49B |
| Short-term investments | $5.64B | $5.54B | $5.79B | $5.49B | $5.94B | $5.47B | $5.26B | $6.52B |
| Receivables | $7.58B | $6.57B | $5.73B | $5.74B | $5.69B | $5.61B | $5.56B | $6.21B |
| Inventory | $2.89B | $3.08B | $3.10B | $3.20B | $3.25B | $3.21B | $3.19B | $3.09B |
| Current assets | $20.80B | $18.45B | $18.21B | $18.02B | $17.98B | $16.86B | $17.57B | $18.66B |
| PP&E, net | $5.73B | $5.46B | $5.27B | $5.12B | $5.00B | $4.84B | $4.69B | $4.60B |
| Intangibles | $1.32B | $1.31B | $1.29B | $1.26B | $1.38B | $1.35B | $1.17B | $1.15B |
| Total assets | $44.41B | $41.73B | $40.87B | $40.56B | $40.17B | $38.22B | $37.55B | $37.76B |
| Current liabilities | $6.20B | $5.53B | $5.11B | $4.37B | $4.43B | $3.67B | $3.57B | $3.94B |
| Long-term debt | $1.99B | $1.99B | $1.99B | $1.99B | $1.99B | $1.99B | $1.98B | $1.98B |
| Total debt | $1.99B | $1.99B | $1.99B | $1.99B | $1.99B | $1.99B | $1.98B | $1.98B |
| Total liabilities | $10.91B | $10.02B | $9.45B | $9.30B | $9.21B | $8.28B | $8.16B | $8.41B |
| Shareholders' equity | $33.50B | $31.71B | $31.42B | $31.26B | $30.96B | $29.94B | $29.39B | $29.35B |
| Net debt | -$1.67B | -$469.20M | -$976.40M | -$1.13B | -$520.90M | -$10.70M | -$1.11B | -$504.60M |
| Cash flow statement | ||||||||
| Operating cash flow | $1.78B | $813.00M | $1.08B | $1.17B | $1.62B | $1.14B | $1.05B | $1.26B |
| Capital expenditure | $300.20M | $240.20M | $230.60M | $248.70M | $201.40M | $219.00M | $229.30M | $199.60M |
| Free cash flow | $1.48B | $572.80M | $848.30M | $922.00M | $1.42B | $925.40M | $815.80M | $1.06B |
| Investing cash flow | -$288.10M | -$92.70M | -$428.90M | $220.30M | -$402.90M | -$1.09B | $647.50M | $350.60M |
| Financing cash flow | -$290.20M | -$1.22B | -$802.20M | -$780.10M | -$717.90M | -$1.13B | -$1.09B | -$1.14B |
| Depreciation & amortization | $121.00M | $123.70M | $123.20M | $145.00M | $136.70M | $135.10M | $126.90M | $126.40M |
| Stock-based compensation | $255.80M | $243.00M | $257.40M | $249.30M | $237.00M | $251.70M | $255.70M | $304.40M |
| Dividends paid | $95.70M | $96.80M | $97.80M | $92.70M | $91.20M | $92.60M | $93.80M | $0 |
| Share buybacks | $399.70M | $1.17B | $794.30M | $671.70M | $664.00M | $1.06B | $1.04B | $973.00M |
Free plan shows the latest 8 periods; Pro shows all 70 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.